Objectives : 

To provide Clinical/Scientific information to fellow members and public at large 

To organize and conduct relevant Stroke-related research  

To provide Clinical and Scientific Information

It was proposed that the Home address should be easier to remember and index. The name was revised and suggested as :

http://www.stroke.org.hk

It was suggested by Mr. Andrew Mallard that the new site could be tested on his web site first. When the contents were fully checked for copyrights and agreed by the executive members, the site could be released worldwide. By then, an independent web site should purchase by the Society and maintained thereon.

 The content of the website should include :

· A territories wide Stroke Registry

· Evidence Based Medicine on Stroke

· Discussion Forum on Stroke

· Email post office with email addresses for members of the Stroke Society

· Email address suggested was info@stroke.org.hk 

Scientific Committee Proposal : 

 Creation of territories wide Stroke Registry – Web enabled 

For better communication with clinician from all sectors

Stroke information for patient and clinician.

Building of web page for the stroke society

Evidence based medicine

Discussion Forum

Email address

Stroke rehabilitation

Surgical treatment options

Endovascular treatment modality for haemorrhagic stroke

Thrombolysis current trend

Patient center page

Research 

Collection of data

Common clinical problems --- for studying rare cases e.g. Moya Moya

Cooperative research studies –e.g. Warfarin INR safety issue - ? Chinese population data

Warfarin related complication of all hospitals.

Topic convener –

It was suggested that several topic conveners should be appointed to conduct analysis of data say every 6 months

Members have to consider the seeking of Sponsorship of a research assistance

Looking for the most insterested topics – only a few topic first and then focus on the most important ones.

Establish a central convener for drilling down for detail topics.

CME – eKG – like information for distribution from the Society.

Protocols and Guideline 

We should pursuit the unification of protocols and guideline for stroke management territories wide.

Suggestions include:

How to improve the service and treatment methods.--- may be duplicated HA effort.

Dissection of carotid or Moya Moya can be something not done by HA.

Required to include private sector – pushing HA to move in a different direction

Or vise versa 

Influence on policy  

We should try to modify HA policy in stroke to suit our society or the population at large. The modify the framework for the use by even Mainland Chinese organization.

Standard and benchmarking could be established--- independent statement e.g. treatment of intracerebral clot to suit the local context.

e.g. thrombolysis --- if all private and public contribute to the society database, then we can assess the true picture of the goal of achievement e.g. the therapeutic window.

Establishing Authority  

e.g. Chinese medicine ---- effectiveness of treatment. Taking advantage of neutrality can study of chinese medicine.

Window of opportunity to get funding from foreign chinese drug company

Cooperation in drug trial.

How to organize control trial. Can be used under Health food.

Dan Sum, or Kor Gun trials ----- check of efficacy.

Need search of suitable drug candidate.

With the recognition established, the Society could go on the meet with Chinese organization --- to find out suitable drug for trial.

e.g. Sometime in July to start cooperation in trial.

Forming a group for clinical trial

1/ Prof. Nancy Ip from UST/ Dr.Vivian Wong HA

2/ Anatomy professor – Chinese U molecular science.

Focus of stroke related TCM

Interaction with basic scientists /pharmacological research

Divided into interest groups for discussion

On Cerebral haemorrhage. 

Suggestions :

What is the current method in the treatment of cerebral haemorrhage in Hong Kong? - operative or non operative 6 months outcome

All member to fill in the form \ check the accuracy of data, admission BP, volume etc need to be added to the dataset.

Radomized trial on medical treatment. What about Blood pressure control during or after operative treatment for cerebral haemorrhagic stroke. Relationship to ICP.

Radomized trial in antifibrinolytic agent e.g. Transamine on cerebral haemorrhage.

On vascular abnormality 

Suggestions :

cavernous haemangioma – bleeding rate ? benign or potentially dangerous ? annual occurance rate ?

AVM cannot fully surgically treat, is antifibrinolytic drug of any use? Can it reduce rebleeding of AVM? Event rate is it high or low / statistic significant study evaluation. An AVM registry.